Burnett Patrick sold $46K of ARQT

Burnett Patrick (See Remarks) sold 1,697 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $27.00 on 2026-08-19.

Original reporting
SEC EDGAR · Burnett Patrick
Published Aug 21, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARQT
Neutral
low confidence
Mentioned
$ARQT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to affect ARQT's share price materially.

02

Market read

Minor insider sale with limited trading relevance.

03

What to watch

Potential upcoming clinical data or regulatory events not disclosed in the filing.

Relevance 3/10Novelty 4/10Timing: today

Background

Form 4 filings disclose insider transactions; traders monitor them for signals.

Company-level read

Ticker impact

$ARQTNeutralLow confidence
Context

Officer Burnett Patrick sold 1,697 shares of Arcutis Biotherapeutics for $45,819 in a Form 4 filing.

Expected impact

minimal impact; price likely unchanged

Evidence & confidence

The sale represents less than 1.5% of the insider's remaining stake and is under $50k, unlikely to move the market.

Market effects

None; biotech sector not affected by a single small insider sale.

None; the filing is U.S.-based with no broader regional effect.

None; no global market relevance.

Counterpoint

The insider may be diversifying without negative outlook; could be neutral or positive for the stock.

Key entities

  • Arcutis Biotherapeutics, Inc.

    Biotech firm developing dermatology therapies.

  • Burnet Patrick

    Company officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.